期刊文献+

替加环素体外抗菌活性检测方法的分析评价 被引量:2

Analysis and Evaluation of in vitro Antimicrobial Susceptibility Test for Tigecydine
原文传递
导出
摘要 目的通过纸片扩散(KB)法、最小抑菌浓度检测试纸条(MTS)及Vitek 2 Compact系统检测临床常见多重耐药菌对抗菌药物替加环素的体外敏感性,从而评价3种体外药物敏感试验检测的准确性。方法回顾性收集2014年1月-2015年3月分离的140株临床常见的多重耐药菌(不含铜绿假单胞菌),其中非发酵菌鲍曼不动杆菌119株,肠杆菌科21株。采用KB法、Vitek 2法和MTS法检测替加环素的最小抑菌浓度值,并将Vitek 2法和KB法的结果与MTS法进行比较。结果 MTS法、KB法和Vitek 2法检测119株鲍曼不动杆菌对替加环素敏感率分别为90.8%、88.2%、85.7%,差异无统计学意义(P>0.05);检测21株肠杆菌科菌对替加环素敏感率分别为81.0%、76.2%、81.0%,差异无统计学意义(P>0.05)。结论替加环素对铜绿假单胞菌以外的临床常见多重耐药菌具有较好的体外抗菌活性,但是不同的检测方法敏感率有所不同,均存在差异。对于鲍曼不动杆菌,KB法优于Vitek 2法;对于肠杆菌科菌,Vitek 2法检测结果优于KB法。 Objective To detect the in vitro susceptibility of common clinical multidrug-resistant bacteria to tigecycline by disk diffusion(KB),minimum inhibitory concentrations(MIC) test strip(MTS) and Vitek 2 Compact methods,in order to evaluate the accuracy of the three different susceptibility testing methods.Methods A total of140 multidrug-resistant isolates(excluding Pseudomonas aeruginosa) were collected retrospectively from West China Hospital between January 2014 and March 2015.The inhibitory zone diameters and MIC of tigecycline were determined by KB,Vitek 2 Compact system and MTS respectively.The results of Vitek 2 Compact system and KB method were compared with that of MTS.Results Among the 140 multidrug-resistant isolates,119 were Acinetobacter baumannii,and 21 were Enterobacteriaceae.According to the US Food and Drug Administration standards,the sensitivity rates of 119 Acinetobacter baumannii isolates to tigecycline were 88.2%,85.7%,and 90.8%respectively for KB method,Vitek 2 Compact system and MTS,and those of 21 Enterobacteriaceae were 76.2%,81.0%,and 81.0%,respectively.Conclusions Tigecycline displays effective in vitro antibacterial activity to clinical common multidrug-resistant bacteria(excluding Pseudomonas aeruginosa),but different susceptibility testing methods have shown different susceptibility rates.For Acinetobacter baumannii,KB method is superior to Vitek 2 Compact system,and for Enterobacteriaceae,Vitek 2 Compact system is superior to KB method.
出处 《华西医学》 CAS 2016年第10期1697-1700,共4页 West China Medical Journal
关键词 替加环素 鲍曼不动杆菌 肠杆菌科 药物敏感性试验 Tigecycline Adnetobacter baumannii Enterobacteriaceae Antimicrobial susceptibility test
  • 相关文献

参考文献18

  • 1朱德妹,汪复,胡付品,蒋晓飞,倪语星,孙景勇,徐英春,张小江,胡云健,艾效曼,俞云松,杨青,孙自镛,陈中举,贾蓓,黄文祥,卓超,苏丹虹,魏莲花,吴玲,张朝霞,季萍,王传清,王爱敏,张泓,孔菁,徐元宏,沈继录,单斌,杜艳.2010年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2011,11(5):321-329. 被引量:651
  • 2中华人民共和国卫生部.多重耐药菌医院感染预防与控制技术指南(试行)[EB/OL].(2011-01-26)[2011-04-20].http ://www. moh. gov. cn.
  • 3Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to beta-Lactamase Klebsiella pneurnoniae Carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes[J]. Clin Infect Dis, 2010, 50(3): 364-373.
  • 4CLSI. Performance standards for antimicrobial disk susceptibility tests; approved standard-tenth edition. CLSI document M02-A10[S]. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
  • 5王辉,倪语星,陈民钧,胡必杰,王明贵,陈佰义,胡继红,胡云建.新型甘氨酰环素类抗菌药物替加环素的体外药敏试验操作规程[J].中华检验医学杂志,2009,32(11):1208-1213. 被引量:65
  • 6胡必杰.转变观念 改革系统 共创医院感染“零宽容”[J].中华内科杂志,2007,46(9):708-709. 被引量:30
  • 7Liao CH, Kung HC, Hsu GJ, et al. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods[J]. Int J Antimicrob Agents, 2008, 32 (Suppl 3): S192-S196.
  • 8张冀霞,赵春江,刘文云,严薇,彭秋生,王占伟,王辉.替加环素对鲍曼不动杆菌和肺炎克雷伯菌体外抗菌活性检测的影响因素和方法学评估[J].中华检验医学杂志,2013,36(7):604-609. 被引量:23
  • 9杜小幸,王海萍,傅鹰,陈衍,俞云松.不同药敏方法检测替加环素对鲍曼不动杆菌敏感性的比较[J].中华检验医学杂志,2013,36(7):598-603. 被引量:22
  • 10Zarkotou O, Pournaras S, Altouvas G, et al. Comparative evaluation of tigecycline susceptibility testing methods for expanded- spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens[J]. J Clin Microbiol, 2012, 50(11): 3747-3750.

二级参考文献68

  • 1Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother, 1999, 43:738-744.
  • 2Bradford P. Tigecycline: a first in class glycylcycline. Clin Micro Newsl, 2004,26:163-168.
  • 3Felmingham D. Tigecycline-the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline. J Chemother, 2005,17 Suppl 1:5-11.
  • 4Chopra I, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother,1992 ,29 :245-277.
  • 5Schnappinger D, Hillen W. Tetraeyclines: antibiotic action, uptake, and resistance mechanisms. Arch Mierobiol, 1996, 165:359-369.
  • 6Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drugdirected Fe^2 + cleavage of 16S rRNA. J Antimicrob Chemother, 2004, 53:592-599.
  • 7Olson MW, Ruzin A, Feyfant E, et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother, 2006,50 : 2156 -2166.
  • 8Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Mierob Drug Resist, 2007,13:1-6.
  • 9Ruzin A, Visalli MA, Keeney D, et al. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother,2005,49 : 1017-1022.
  • 10Visalli MA, Murphy E, Projan SJ, et al. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline ( GAR- 936) in Proteus mirabilis. Antimicrob Agents Chemother. 2003.47,665-669.

共引文献769

同被引文献9

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部